for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Co-Diagnostics Inc

CODX.OQ

Latest Trade

15.96USD

Change

0.00(0.00%)

Volume

51,459

Today's Range

--

 - 

--

52 Week Range

0.70

 - 

19.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
15.96
Open
0.00
Volume
51,459
3M AVG Volume
124.78
Today's High
--
Today's Low
--
52 Week High
19.65
52 Week Low
0.70
Shares Out (MIL)
24.92
Market Cap (MIL)
221.75
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Co-Diagnostics Announces $5.0 Mln Registered Direct Offering Priced At-The-Market

Co-Diagnostics Designs Test For New Coronavirus Using Coprimer Platform

Co-Diagnostics Reports JV In India Has Been Notified That Regulatory Approval Is Imminent

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Co-Diagnostics Inc

Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

Contact Info

4049 S Highland Dr

+1.801.2789769

http://codiagnostics.com/

Executive Leadership

Dwight H. Egan

Chairman of the Board, President, Chief Executive Officer

Reed L. Benson

Chief Financial Officer, Secretary

Brent Satterfield

Chief Scientific Officer

Eugene Durenard

Independent Director

Edward L. Murphy

Independent Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-0.500

2019(E)

-0.360
Price To Earnings (TTM)
--
Price To Sales (TTM)
1,891.75
Price To Book (MRQ)
46.28
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-318.25
Return on Equity (TTM)
-196.43

Latest News

Latest News

BRIEF-Co-Diagnostics Announces $4.2 Million Registered Direct Offering Priced At-The-Market

* CO-DIAGNOSTICS ANNOUNCES $4.2 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

BRIEF-Co-Diagnostics Receives CE Mark For Novel Coronavirus Test

* CO-DIAGNOSTICS, INC. RECEIVES CE MARK FOR NOVEL CORONAVIRUS TEST

BRIEF-Co-Diagnostics Completes Submission Of CE Marking Registration For COVID-19 Coronavirus Test

* CO-DIAGNOSTICS COMPLETES SUBMISSION OF CE MARKING REGISTRATION FOR COVID-19 CORONAVIRUS TEST

BRIEF-Co-Diagnostics To Present Its Rapid Response To New Coronavirus In Washington D.C. Conference

* CO-DIAGNOSTICS, INC. TO PRESENT ITS RAPID RESPONSE TO NEW CORONAVIRUS IN WASHINGTON D.C. CONFERENCE Source text for Eikon: Further company coverage:

BRIEF-Co-Diagnostics Announces $10.2 Million Registered Direct Offering Priced At-The-Market

* CO-DIAGNOSTICS ANNOUNCES $10.2 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

Gilead working with China to test Ebola drug as new coronavirus treatment

Gilead Sciences Inc <GILD.O> said on Friday it provided its experimental Ebola therapy for use in a small number of patients with the coronavirus that has killed over 200 so far in China and is working with the country's authorities to set up a study.

BRIEF-Co-Diagnostics Announces Construction Update At Facility In India

* CO-DIAGNOSTICS, INC. ANNOUNCES CONSTRUCTION UPDATE AT JV MANUFACTURING FACILITY IN INDIA

BRIEF-Co-Diagnostics Inc Announces Positive Results From Co-Primers Technology In Multiplex Tests For SNP Detection

* CO-DIAGNOSTICS INC ANNOUNCES POSITIVE RESULTS FROM CO-PRIMERS™ TECHNOLOGY IN MULTIPLEX TESTS FOR SNP DETECTION Source text for Eikon: Further company coverage:

BRIEF-Co-Diagnostics Enters Into Lease For Upgraded Laboratory Facility In Salt Lake City

* CO-DIAGNOSTICS - ENTERS INTO LEASE FOR BIOLOGICAL SAFETY LEVEL 2 LABORATORY FACILITY IN SALT LAKE CITY, UTAH

BRIEF-Co-Diagnostics to sign purchase agreement with Medcis Pathlabs

* Co-Diagnostics, Inc to sign purchase agreement with Medcis Pathlabs

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up